http://www.fpnotebook.com/
Polycystic Ovary Disease
Aka: Polycystic Ovary Disease, Stein-Leventhal Syndrome, Polycystic Ovary Syndrome, Polycystic Ovaries, Functional Ovarian Hyperandrogenism, PCO Disease, PCOS- See Also
- History
- First described by Stein and Leventhal in 1935
- Pathophysiology
- Contributing Factors
- Obesity and hyperinsulinemia
- Increased adrenal function
- Androgen Excess (Hyperandrogenism)
- Androstenedione increased
- Testosterone increased
- Free Testosterone increased
- Occurs with decreased Sex Hormone Binding Globulin
- Ovarian enlargement with Hyperthecosis
- Luteinization of theca interna
- Reduction of granulosa cells
- Contributing Factors
- Symptoms
- Menstrual Disorders (80% of PCOS patients)
- Anovulatory Bleeding (<6 Menses per year)
- Delayed menstrual regularity
- Infertility (74%) and Recurrent Miscarriage
- Androgenic features
- See Hyperandrogenism
- Acne Vulgaris
- Hirsutism (69%)
- Male sweat changes
- Clitoris swelling
- Central Obesity (49% of PCOS patients)
- Weight gain starts in teens and twenties
- BMI over 27 (65% of PCOS patients)
- Mood disturbance (e.g. Major Depression, Anxiety)
- Menstrual Disorders (80% of PCOS patients)
- Signs
- Hirsutism
- Bilateral ovary enlargement
- Hypertension
- Differential Diagnosis (See Hyperandrogenism)
- Cushing's Syndrome and other endocrinopathies
- Adrenal Hyperplasia
- HAIR-AN Syndrome
- Radiology: Transvaginal Ultrasound
- General features
- Multiple small follicles in various stages
- Thick ovarian capsule
- String of pearls appearance
- Criteria: Multiple Ovarian Cysts (seen in 80% of cases)
- Ten or more cysts in a single plane
- Each cyst <10 mm in diameter
- Dense stroma
- Interpretation
- Polycystic appearance is seen in up to 33% of women
- Polycystic appearance does not diagnose PCOS
- PCOS clinical features must be present for diagnosis
- Hassan (2003) Fertil Steril 80:966-75
- General features
- Labs: Approach
- Screening for PCOS (if history suggests)
- Glucose to Insulin Ratio < 4.5
- Exclude other diagnoses
- Thyroid Stimulating Hormone
- Morning 17a-hydroxyprogesterone (adrenal hyperplasia)
- Serum DHEAS > 700 ng/dl (Androgen secreting tumor)
- Serum Total Testosterone >20 ng/dl (Androgen tumor)
- Evaluate comorbid disease
- Screening for PCOS (if history suggests)
- Labs: Review of laboratory changes in PCOS
- Insulin Resistance Syndrome (70% of PCOS patients)
- Glucose to Insulin Ratio < 4.5
- Sensitive marker of Insulin Resistance in PCOS
- Insulin increased (C-Peptide increased)
- Fasting Serum Glucose increased
- Two hour Glucose Tolerance Test abnormal
- Glucose to Insulin Ratio < 4.5
- Gonadotropin increases
- Luteinizing hormone (LH) exaggerated surge
- Serum LH to Serum FSH ratio exceeds 3.0 (30%)
- Serum Testosterone >20 ng/dl
- Serum Free Testosterone >2.57 pg/ml
- Androstenedione >2.7 ng/ml
- Associated endocrine abnormality testing
- Thyroid Stimulating Hormone (TSH)
- Serum Prolactin
- Consider adrenal function testing
- Associated dyslipidemia
- Total Cholesterol increased
- LDL Cholesterol increased
- HDL Cholesterol decreased
- Triglycerides increased
- Insulin Resistance Syndrome (70% of PCOS patients)
- Management: General
- Weight loss of 10% in Overweight patients
- Insulin Resistance decreases with weight loss
- Results in 75% conception rate in PCOS
- Weight loss of 10% in Overweight patients
- Management: Unopposed Estrogen Management
- Provera 10 mg PO qd for 7 days repeated q3 months or
- Oral Contraceptive with low Androgenic Activity
- Management: Ovulatory Dysfunction interfering with fertility
- Clomiphene (Clomid)
- Letrozole (Femara)
- Management: Hyperandrogenism (e.g. Hirsutism, Acne)
- See HAIR-AN Syndrome
- See Hirsutism
- First-Line Agents
- Spironolactone (Aldactone) 50 mg PO twice daily
- Eflornithine (Vaniqa) 13.9% applied to face daily
- Second-Line Agents
- Finasteride (Propecia)
- Flutamide (Eulexin)
- Management: Insulin Resistance
- Metformin (Glucophage)
- Start at 500 mg PO daily and advance to 1500-2000 mg daily divided bid
- Effect not seen until dose >1000 mg/day
- Induces Ovulation in up to 46% of PCOS cases
- Barbieri (2003) Obstet Gynecol 101:785-93
- Lord (2003) BMJ 327:951-6
- Glitazones
- Pioglitazone (Actos) 30 mg orally daily
- Rosiglitazone (Avandia) 2-8 mg orally daily (best effect with higher doses)
- Metformin (Glucophage)
- Management: Advanced
- Gonadotropins (e.g. Metrodin, Pergonal)
- Risk of Ovarian Hyperstimulation Syndrome (OHSS)
- FSH with hCG
- Glucocorticoids (Prednisone, Dexamethasone)
- Indicated in adrenocortical hyperplasia
- GnRH-agonist
- Indicated prior to Ovulation induction
- Gonadotropins (e.g. Metrodin, Pergonal)
- Management: Surgical
- Ovarian wedge resection
- Normal cycles resume in 80% of patients
- Conception occurs in 63%
- Risk of peritubular and ovarian adhesions
- Laparoscopic ovarian drilling
- Similar results to ovarian wedge resection
- Minimally invasive
- Ovarian wedge resection
- Complications
- Infertility
- Increased Breast Cancer risk
- Increased Endometrial Cancer risk
- Associated with Unopposed Estrogen
- Increased cardiovascular disease risk
- References